CEACAM-1

CEACAM-1

CEACAM-1 詳細

Molecule Name
Carcinoembryonic antigen related cell adhesion molecule 1
分子の別称
CEACAM1,CD66a,BGP,BGP1,BGPI
Drug Development Progress
治験薬の数1
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
CEACAM1,Biliary glycoprotein 1,BGP,CD66a,Carcinoembryonic Antigen Related Cell Adhesion Molecule 1,CD66a Antigen,BGP1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1,Antigen CD66,BGP-1,BGPI,CEA Cell Adhesion Molecule 1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein)
バックグランド
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a, which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.

CEACAM-1 製品リスト

Species
  • Human(2)
  • Cynomolgus(1)
Tag
  • His Tag(2)
  • His Tag & Avi Tag(1)
Host
  • HEK293(3)
Conjugate
  • Unconjugated(2)
  • Biotin-labeled(1)
Grade
  • RUO(3)
Low Endotoxin
  • Yes(1)
  • No(2)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
CEACAM-1
Cynomolgus CEACAM-1 / CD66a Protein, His Tag
Cynomolgus
HEK293
SDS-PAGE

$360.00

100ug
CEACAM-1
Human CEACAM-1 / CD66a Protein, His Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISA

$285.00

100ug
CEACAM-1
Avitag
CE1-H82E5
Biotinylated Human CEACAM-1 / CD66a Protein, Avitag™,His Tag
Human
HEK293
SDS-PAGE
ELISA

$360.00

25ug
You Have Viewed 1-3 Of 3 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
CM-24CM-24 (MK-6018); MK-6018; CM-24Phase 2 ClinicalMerck Sharp & Dohme Corp
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Urinary Bladder Neoplasms
詳細
Customer Reviews